VIVUS Inc. (VVUS)

4.10
NASDAQ : Health Technology
Prev Close 4.16
Day Low/High 3.98 / 4.20
52 Wk Low/High 2.15 / 5.78
Avg Volume 108.20K
Exchange NASDAQ
Shares Outstanding 10.64M
Market Cap 44.27M
EPS -3.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Positive News Sparks Shares

A clinical study shows this name's obesity drug could also help treat sleep apnea. Here's our take.

FDA to Review Amgen Drugs: BioBuzz

FDA to Review Amgen Drugs: BioBuzz

FDA will re-examine the safety of Amgen's anemia drugs, while Vivus' weight-loss drug posts win in small sleep apnea study.

Stocks Under $10 Weekly Summary

Keeping an eye on 2010 as we close out a relatively uneventful week for the model portfolio.

An Important Update

This model portfolio name has applied for FDA approval of its obesity drug. Here are the details.

Vivus Files For Approval Of Obesity Drug Qnexa

Vivus says it asked FDA for marketing approval of its obesity drug candidate Qnexa

Stocks Under $10 Weekly Summary

There was surprisingly heavy news flow in the model portfolio this week, and we took profits on one holding.

Updating Two Names

One name is trading higher on news in the obesity-drug area while another trading lower after a downgrade.

Arena Files For FDA Approval Of Obesity Drug

Arena Pharma asks for marketing approval of lorcaserin; 2 rivals may follow suit in 2010

Stocks Under $10 Weekly Summary

We used the volatility in the market this week to initiate a new position and make some moves in the model portfolio.

Arena Shares Fall On Jefferies Coverage, Caution

Arena Pharmaceuticals shares fall on Jefferies analyst 'Hold' rating, view on obesity drug

Two Names in the News

A pair of model portfolio names are trading higher today -- one on takeover rumors and the other on new analyst coverage.

Stocks Under $10 Weekly Summary

This week, we freed up some cash in anticipation of further buying opportunities for the model portfolio.

Stocks Under $10 Weekly Summary

In a week that ended with a positive jobs number, we continued to research potential new names for the model portfolio.

Biotech Calendar: Key Dates for December

Biotech Calendar: Key Dates for December

A calendar of important, potentially stock-moving biotech events for December.

Stocks Under $10 Weekly Summary

We focused on researching new names for the model portfolio this week and used Friday's pullback to add shares to one holding.

Poniard Finds Cash to Keep Lights On: BioBuzz

Poniard Finds Cash to Keep Lights On: BioBuzz

Poniard faces a cash-crunch situation after a failed drug test last week.

A Pair of Updates

Two model portfolio names are in the news today amid chatter on an obesity-drug study and a takeout rumor.

Cel-Sci Chairman Sells Stock, Despite Sweetheart Loan Deal: BioBuzz

Cel-Sci Chairman Sells Stock, Despite Sweetheart Loan Deal: BioBuzz

Shareholders are on the hook for a generous loan repayment to Cel-Sci's founder.

FDA Issues New Obesity Drug Heart Warning: BioBuzz

Safety of Abbott's Meridia may heighten concerns for all weight-loss drugs

Stocks Under $10 Weekly Summary

We put some cash to work this week as the model portfolio's benchmark, the Russell 2000, fell for four straight days.

Biotech Stock Mailbag: FDA Playbook

Smart drug and biotech companies keep the FDA abreast of their clinical trial program throughout the long drug-development process.

Poised for a Purchase

This pharmaceutical name is trading lower on the session, but we will continue to monitor the price action before taking action.

Coventry, BJ's Wholesale, Vivus Are Big Movers

Coventry, BJ's Wholesale, Vivus Are Big Movers

Coventry, BJ's Wholesale, Vivus, Smith International are among big market movers Wednesday

Vivus Shares Rise On Positive Avanafil Study Data

Vivus Shares Rise On Positive Avanafil Study Data

Vivus shares rise as erectable dysfunction drug avanafil meets late-stage study goal

A Robust Update

Shares of this recent model portfolio addition are surging on strong trial results for its erectile dysfunction drug.

Another Genzyme Drug Goes Kaboom: BioBuzz

Another Genzyme Drug Goes Kaboom: BioBuzz

Company halts development of kidney disease drug following poor test results.

Vivus Seeks Faster ED Drug: Biobuzz

Company says ED drug met all goals in phase III study.

Vivus Says ED Drug Avanafil Met Goal In Trial

Vivus says all doses of avanafil improved erectile function, reaching late-stage trial goal

Stocks Under $10 Weekly Summary

We took advantage of the relative weakness in the small-cap universe to add two new names to the model portfolio this week.

Weighing In on a New Name

Despite the risky nature of the biotech sector, this company has the potential to be a Game Breaker.

TheStreet Quant Rating: D (Sell)